our nasal vaccine platform

Background

Almost all viruses, including Coronavirus, Influenza and Respiratory Syncytial Virus (RSV), gain entry by binding to receptors present on luminal mucosal epithelial cell surfaces. To counter the influx of pathogens, mammals have developed an innate mucosal immune system as a first line of defense, blocking or destroying foreign particles right at the port of entry.

Today, most vaccines are being administered by intramuscular injection, activating the systemic immune system but not the mucosal immune system. While these vaccines are effective at preventing severe diseases and death, they do little to actually prevent viral infection and spread.

We offer a different approach.

Photo credit: CDC

why nasal vaccines against respiratory infections?

Photo credit: CDC

For more information, visit our related articles or contact us pages.

What makes us different among nasal vaccines

bronchia

We exploited this property of FcRn: our vaccines are fusions with the human IgG Fc region